Congress Program

Monday, 19 February

 08:00  Registration
 08:50  Congress Opening and Welcome from Congress Chair
 09:00  Session I: Keynote Presentation
 
Moderator: Raanan Berger, Israel, Congress Chair

09:00-09:30
Pitfalls and Opportunities in Personalized Cancer Medicine: What Have We Learned?
Diane SimeoneLaura and Isaac Perlmutter Professor of Surgery and Pathology at New York University and the Director of the Pancreatic Cancer Center at NYU Langone Health, USA

 09:30  Session II:  Clinical Trials beyond the Patient
 
Moderator: Talia Golan, Israel, Organizing Committee

09:30-09:50
Oncology Clinical Trial Operations eg RECIST and Lugano Criteria
Rachel Schor-Bardach, Radiologist, Oncological Imaging and Cross-Sectional Imaging Section, Chaim Sheba Medical Center, Israel

09:50-10:10
Personalizing the Tumor Micro Environment in Clinical Trials
Aaron Goldman
, Associate Director, Research and Development and Immuno Oncology, Mitra Biotech, USA

10:10-10:30
Data Management in Oncology Clinical Trials 
Maria A. CrazeHeadquarters Director of Global Data Operations, Merck & Company, Inc, USA

10:30-10:45
Discussion 

 10:45  Coffee Break, Poster Viewing and visit the Exhibition
 11:15  Session III: Clinical Trials in Hematology 
 
Moderator:
 Clemens-Martin Wendtner, Germany

11:15-11:35
CAR T Cell Therapies Developed/Co-Developed by Celgene
Michael ZaiacVice President, Head of Haematology/Oncology Medical Affairs EMEA, Celgene, Switzerland

11:35-11:55
Fighting Hematological Diseases with an Innovative Approach: CAR-T Therapy
Simona Maria Paratore
, Medical Head, Cell and Gene Therapy, Novartis Oncology Region Europe, Italy

11:55-12:15
The GIMEMA [Gruppo Italiano Malattie Ematologiche dell’Adulto] Framework for Clinical Trials in Hematology in Italy
Marco Vignetti, Dept. of Cellular Biotechnologies and Hematology, Sapienza University and Director, Central Office, GIMEMA Research Foundation, Rome, Italy

12:15-12:35
The German CLL Study Group
Clemens-Martin WendtnerDirector, Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases, and Tropical Medicine, Klinikum Schwabing, Munich, Germany

12:35-12:55
The Impact of Clinical Trials in the Management of ALL
Sabina ChiarettiDiv. of Hematology, Dept. of Cellular Biotechnologies and Hematology, Sapienza University, Italy

 13:00 Lunch Break, Poster Viewing and visit the Exhibition
 14:00  Session IV: Finance & Oversight in Oncology Clinical Trials 
 
Moderator: Aliza Ackerstein, Israel, Organizing Committee

14:00-14:20
Budgeting Clinical Trials in Oncology
Ivana Matic, Global Operations Lead – Agreements
, MSD, Belgium  


14:20-14:40
How Pharma Companies Retain Ownership & Oversight in Pharma/CRO Alliance Models
Daniela Abbiento, Associate Director, Site Relationship and Operational Lead, Merck Group, Italy

14:40-15:00
Panel Discussion

 15:00
15:00-15:30
Sponsored Lecture supported by GlobalCare Clinical Trials
Oncology Studies Facilitated by Taking Study Visits to the Patients
Gail Adinamis, Founder & CEO, GlobalCare Clinical Trials, USA

 15:30  Coffee Break, Poster Viewing and visit the Exhibition
 15:50  Session V: Pre-Clinical Models 
 
Moderators: Jens Siveke, Germany, Organizing Committee

15:50-16:10
Pre-Clinical Models and How they Influence Clinical Trial Decisions- The Physician Perspective (Pitfalls and Problems) 
Jens Siveke, Director, Division of Solid Tumor Translational Oncology at the partner site Essen of the German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ) and Head of the Clinical Pancreatic Cancer Program at the West German Cancer Center, University Hospital Essen, Germany

16:10-16:30
Patient Xenograft Models: Tool for Preclinical Phase II Studies?
Jens Hoffmann, CEO, EPO-Berlin-Buch GmbH, Germany

16:30-17:00
Lost in Translation: Preclinical Modeling in Pancreatic Cancer - Where Do We Go from Here?
Vincenzo Corbo, University of Verona, Italy and  Michele Milella, Regina Elena National Cancer Institute, Italy 

 17:00  End of Day One

 
Tuesday, 20 February 

 07:30 Registration 
 08:30 Session VI: Precision Promise
 
Moderator: 
Victoria Manax, USA

08:30-08:50
Introduction
Victoria Manax, Chief Medical Officer, Pancreatic Cancer Action Network, USA

08:50-09:20
Precision Promise – A New Paradigm in Clinical Trial Design in Pancreatic Cancer 
Diane SimeoneLaura and Isaac Perlmutter Professor of Surgery and Pathology at New York University and the Director of the Pancreatic Cancer Center at NYU Langone Health, USA
 
09:20-09:50
Engaging Industry Partners in Non-Profit-Led, Innovative Clinical Trials: The Precision Promise Experience
Wendy Selig, Founder & CEO, WSCollaborative, USA

09:50-10:20
Design Innovations in Precision Promise: Adaptive Platform Clinical Trial in Pancreatic Cancer  
Donald Berry, Professor, Department of Biostatistics, University of Texas M.D. Anderson Cancer Center, USA 

10:20-10:30
Discussion

 10:30  Coffee Break, Poster Viewing and visit the Exhibition
 11:00  Session VII: Collaborative Organizations and Clinical Trials
 
Moderator: Michele MilellaItaly, Organizing Committee

11:00-11:30
Collaborative Organizations and Clinical Trials - The German Perspective
Salah-Eddin Al-Batran,
Medical Director, Institute of Clinical Cancer Research (ICCR), Krankenhaus Nordwest, 
Germany


11:30-12:00
The Italian Alliance Against Cancer (ACC) Collaborative Effort and a Perspective on Novel Methodological Approaches to Precision Oncology
Gennaro Ciliberto, 
Scientific Director, IRCCS Regina Elena National Cancer Institute, Italy 


12:00-12:30
Discussion
 12:30  Lunch Break, Poster Viewing and visit the Exhibition
 13:30  Session VIII: Criticism, Audits and Inspections and Patient Advocacy
 
Moderator: Talia GolanIsrael, Organizing Committee

13:30-14:00
Criticism of Clinical Trials
Raya Leibowitz-Amit
Physician-Investigator, Chaim Sheba Medical Center, Israel

14:00-14:30
Auditing Oncology Clinical Trials: The FDA Perspective
Marcia Sherry-Newby, Principal Auditor, Chiltern, USA

14:30-15:00
Patient Advocacy in Clinical Trial Design
Tamir Gilat,
Chairman, Israel Cancer Research Fund, Israel

 15:00  Coffee Break, Poster Viewing and visit the Exhibition
 15:30  Session IX: Oral Presentations from Selected Abstracts
 
Moderator: Raanan Berger, Congress Chair

15:30-15:40
Dissecting Response to Targeted Agents in Preclinical Model of Colorectal Cancer (CRC): Role of the Microenvironment
Chiara Bazzichetto, Fabiana Conciatori, Italia Falcone, Francesco Cognetti,
Ludovica Ciuffreda, Michele Milella, Italy

15:40-15:50
Efficacy and Effectiveness of Checkpoint Inhibitors in Randomized Clinical Trials (RCTs) and in Real World Evidence (RWE): The case of Ipilimumab (IPI)
Diana Giannarelli
, Michele Milella, Sabrina Vari, Stefano Molica, Emilio Bria, Italy

15:50-16:00
A Randomized Controlled Trial of Ready to Use Therapeutic Food (RUTF ) For Moderate/Severe Acute Malnourished  Indian Children with Cancer 
Sneha Tandon, Brijesh Arora, Maya Prasad, Shripad Banavali, Gaurav Narula, Meera Gadge, Alka Jadhav, UK

 16:00  End of Congress